Brachytherapy
Volume 5, Issue 1 , Pages 27-31 , January 2006

A simple technique for determining accurate urethral dosimetry after seed brachytherapy for prostate cancer

Received 19 May 2005 ,Revised 15 November 2005 ,Accepted 17 November 2005.

References 

  1. Sylvester JE, Blasko JC, Grimm PD, et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: The Seattle experience. Int J Radiat Oncol Biol Phys. 2003;57:944–952
  2. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003;21:3979–3986
  3. Crook J, Lukka H, Klotz L, et al. Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. CMAJ. 2001;164:975–981
  4. Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol. 2002;41:427–433
  5. Nag S, Ellis RJ, Merrick GS, et al. American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2002;54:462–470
  6. Bucci J, Spadinger I, Hilts M, et al. Urethral and periurethral dosimetry in prostate brachytherapy: Is there a convenient surrogate?. Int J Radiat Oncol Biol Phys. 2002;54:1235–1242
  7. Lee HK, D'Souza WD, Yamal J-MJ, et al. Dosimetric consequences of using a surrogate urethra to estimate urethral dose after brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2003;57:355–361
  8. Sylvester JE, Grimm P, Blasko J, et al. Urethral visualization during transperineal interstitial brachytherapy for early stage prostate cancer. J Brachy Int. 2000;16:145–150
  9. Wallner K, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1995;32:465–471
  10. Desai J, Stock RG, Stone NN, et al. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Investig. 1998;6:135–141
  11. Salem N, Simonian-Sauve M, Rosello R, et al. Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localised prostate cancer: A phase 2 study. Radiother Oncol. 2003;66:159–165
  12. Mallick S, Azzouzi R, Cormier L, et al. Urinary morbidity after 125I brachytherapy of the prostate. BJU Int. 2003;92:555–558
  13. Nag S, Bice W, DeWyngaery K, et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys. 2000;46:221–230
  14. Stock RG, Stone NN. Importance of post-implant dosimetry in permanent prostate brachytherapy. Eur Urol. 2002;41:434–439
  15. Merrick GS, Butler WM, Wallner KE, et al. Dysuria after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55:979–985
  16. Brown D, Colonias A, Miller R, et al. Urinary morbidity with a modified peripheral loading technique of transperineal I-125 prostate implantation. Int J Radiat Oncol Biol Phys. 2000;47:353–360
  17. Chen CT, Waterman FM, Valicenti RK, et al. Dosimetric analysis of urinary morbidity following prostate brachytherapy (125I vs. 103Pd) combined with external beam radiation therapy. Int J Cancer. 2001;96:83–88
  18. Jones S, Wallner K, Merrick G, et al. Clinical correlates of high intraprostatic brachytherapy dose volumes. Int J Radiat Oncol Biol Phys. 2002;53:328–333
  19. Kang SK, Chou RH, Dodge RK, et al. Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method. Int J Radiat Oncol Biol Phys. 2001;50:937–945
  20. Coakley FV, Hricak H, Wefer AE, et al. Brachytherapy for prostate cancer: Endorectal MR imaging of local treatment-related changes. Radiology. 2001;219:817–821
  21. Gelblum DY, Potters L, Ashley R, et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 1999;45:59–67
  22. Lee N, Wuu CS, Brody R, et al. Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;48:1457–1460
  23. Waterman FM, Yue N, Corn BW, et al. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: An analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys. 1998;41:1069–1077
  24. Waterman FM, Dicker AP. Determination of the urethral dose in prostate brachytherapy when the urethra cannot be visualized in the postimplant CT scan. Med Phys. 2000;27:448–451
  25. Al-Qaisieh B. Pre- and post-implant dosimetry: An inter-comparison between UK prostate brachytherapy centres. Radiother Oncol. 2003;66:181–183
  26. Roach M, Faillace-Akazawa P, Malfatti C, et al. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1996;35:1011–1018
  27. Crook JM, Potters L, Stock RG, et al. Critical organ dosimetry in permanent seed prostate brachytherapy: Defining the organs at risk. Brachytherapy. 2005;4:186–194

PII: S1538-4721(05)00201-1

doi: 10.1016/j.brachy.2005.11.001

Brachytherapy
Volume 5, Issue 1 , Pages 27-31 , January 2006

Article Tools

* Image Usage & Resolution